Home / Piperacillin and Beta-Lactamase Inhibitor / Czechia
CZ ATC J01CR05 · updated 2 Nov 2026
Piperacillin and Beta-Lactamase Inhibitor shortage in Czechia
Is there a Piperacillin and Beta-Lactamase Inhibitor shortage in Czechia?
Yes. As of 2 Nov 2026, 1 Piperacillin and Beta-Lactamase Inhibitor product is reported short in Czechia, the first since 1 Mar 2024. The company estimate for the return is 28 Apr 2027. Main reason: commercial decision or withdrawal.
Also short in United States, Canada, Italy, Belgium, Switzerland, Sweden, Japan. All countries.
Affected products in Czechia
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| CZ | PIPERACILLIN/TAZOBACTAM IBIGEN 4G/0,5G 4G/0,5G INF PLV SOL 10 | IBIGEN, S.r.l., Aprilia | 1 Mar 2024 | 28 Apr 2027 | Commercial decision or withdrawal Obchodní/marketingové důvody |
Source
SÚKL (State Institute for Drug Control), market reports. Official list. Products whose latest market report is a supply interruption; one row per SÚKL code.